Lukas Biomedical

Lukas Biomedical OCF Margin

The Operating Cash Flow Margin of Lukas Biomedical (6814.TWO) as of Oct 27, 2026 is -34.22 %. In the previous year, Operating Cash Flow Margin was -37.16 % — a change of -7.90% (higher).

OCF Margin

-34.22 %

YoY

-7.90%

Last updated:

Operating Cash Flow Margin of Lukas Biomedical is 2025 -34.22 % . Operating Cash Flow Margin of Lukas Biomedical was 2024 -37.16 % . It decreases by -7.90% higher compared to the previous year.

The Lukas Biomedical OCF Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

OCF Margin
Date
OCF Margin
Jan 1, 2018
5.57 TWD
Jan 1, 2019
38.62 TWD
Jan 1, 2020
16.00 TWD
Jan 1, 2021
-10.25 TWD
Jan 1, 2022
-4.02 TWD
Jan 1, 2023
-5.07 TWD
Jan 1, 2024
-37.16 TWD
Jan 1, 2025
-34.22 TWD
The Lukas Biomedical OCF Margin history
YEAROCF MarginYoY
-34.22 %-7.90%
-37.16 %+633.32%
-5.07 %+25.92%
-4.02 %-60.74%
-10.25 %-164.04%
16.00 %-58.56%
38.62 %+593.81%
5.57 %-234.18%
-4.15 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Lukas Biomedical Stock analysis

What does Lukas Biomedical do? Lukas Biomedical, Inc. generates revenue through the lease and sale of medical equipment, as well as the research, design, development, and manufacture of immune cell products. The company offers beauty cosmetics, skin care products, and daily necessities such as dental floss, chewing gum, chewing spray, and dry hair products. Its makeup series includes eye shadow gel, eye color palette, lip gloss, lipstick, and lip wax. The firm provides services like brand authorization, management consulting, property leasing, and medical equipment leasing under an experience charging model for care institutions and medical management. The company’s products target consumers in the beauty and healthcare sectors, with medical equipment leased to care institutions and medical management entities. Immune cell products are developed for medical applications, while beauty and daily necessity products cater to personal care markets. The firm’s service model combines brand authorization with property and equipment leasing to support operational experience in healthcare facilities. Lukas Biomedical’s revenue streams include direct sales of medical equipment, lease agreements for medical devices, and the sale of immune cell products, beauty cosmetics, and daily necessities. Care institutions and medical management companies are key clients for leasing services, while beauty product lines serve individual consumers and retail channels. The experience charging model integrates brand authorization and management consulting to enhance service offerings for healthcare providers. Lukas Biomedical is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Lukas Biomedical stock

Operating Cash Flow Margin of Lukas Biomedical is -34.22 % in 2025.

Operating Cash Flow Margin of Lukas Biomedical changed from -37.16 % to -34.22 %, representing a -7.90% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow Margin Lukas Biomedical since 2006 – with annual values, charts, and detailed analysis.

OCF margin measures the percentage of revenue converted into operating cash flow. It indicates cash generation efficiency from core business operations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Cash Flow Margin's Lukas Biomedical with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Cash Flow Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Cash Flow Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Lukas Biomedical

All Key Metrics — Lukas Biomedical